Claims for Patent: 12,152,028

Summary for Patent: 12,152,028

Title:	Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
Abstract:	The present invention provides methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators, and compositions having low impurity levels.
Inventor(s):	Jeffrey Mark Dener, Hazel Joan HUNT, Travis Lemons, Gary Reid, Kilian GARREC, Thomas C. Stephens, Adam Daisuke GAMMACK YAMAGATA, Yunguo LU
Assignee:	Corcept Therapeutics Inc
Application Number:	US17/560,048
Patent Claims:	1. A method of preparing a compound of Formula J: or a pharmaceutically acceptable salt thereof, comprising: (a) forming a first reaction mixture comprising a compound of Formula IIb: and a sulfonyl chloride: to prepare the compound of Formula J in a yield of at least 60% and a purity of at least 98%, wherein X1 is —CH═ or —N═; HX is an acid solvate of HBr, or wherein R1 is C1-6 alkyl; and subscript n is from 1 to 4. 2. The method of claim 1, preparing the compound of Formula I: or a pharmaceutically acceptable salt thereof, comprising: (a) forming the first reaction mixture comprising the compound of Formula IIb: and 1-methyl-1H-pyrazole-4-sulfonyl chloride: to prepare the compound of Formula I in a yield of at least 60% and a purity of at least 98%, wherein HX is the acid solvate; and subscript n is from 1 to 4. 3. The method of claim 1, wherein HX is HBr. 4. The method of claim 3, for preparing the compound of Formula I: or a pharmaceutically acceptable salt thereof, comprising: (a) forming the first reaction mixture comprising a compound of Formula IIb-1: and 1-methyl-1H-pyrazole-4-sulfonyl chloride: to prepare the compound of Formula I in a yield of at least 60% and a purity of at least 98%, wherein the compound of Formula I contains less than 1% (w/w) of a compound of Formula X-5: and wherein subscript n is from 1 to 4. 5. The method of claim 4, wherein the first reaction mixture further comprises a non-nucleophilic amine base. 6. The method of claim 5, wherein the non-nucleophilic amine base comprises trimethyl amine, triethylamine, N,N-diisopropyl ethylamine (DIPEA), N,N-dimethyl isopropylamine (DIMPA), 1-ethylpiperidine, N-methylmorpholine, N-methylpyrrolidine, pyridine, N,N-dimethylaniline, N,N-diethylaniline, 2,6-lutidine, 2,4,6-collidine, 4-dimethyl aminopyridine (DMAP), quinuclidine, 4-pyrrolidinopyridine, 1,4-diazabicyclo[2.2.2]octane (DABCO), or mixtures thereof. 7. The method of claim 5, wherein the non-nucleophilic amine base comprises triethyl amine. 8. The method of claim 4, wherein the sulfonyl chloride is present in a molar ratio of 1.2 to 2.3 to the compound of Formula IIb-1. 9. The method of claim 4, further comprising after step (a): (a1) mixing the first reaction mixture with water having a pH of between 4 and 5 to form a first organic phase and a first aqueous phase; (a2) mixing the first organic phase with water and sodium chloride wherein the water has a pH of between 5 and 6; and (a3) mixing the first organic phase and silica gel. 10. The method of claim 4, wherein the compound of Formula IIb-1 is prepared by the step of: (b) forming a second reaction mixture comprising a compound of Formula IIa: and gaseous HBr, to form the compound of Formula IIb-1 having the structure: 11. The method of claim 4, wherein the compound of Formula I is prepared by the steps of: (b) forming the second reaction mixture comprising a compound of Formula IIa: and gaseous HBr, to form the compound of Formula IIb-1 having the structure: and (a) forming the first reaction mixture comprising the compound of Formula IIb-1: triethylamine, and 1-methyl-1H-pyrazole-4-sulfonyl chloride: wherein the sulfonyl chloride is present in a molar ratio of about 1.2 to the compound of Formula IIb-1; (a1) mixing the first reaction mixture with water having a pH of between 4 and 5 to form a first organic phase and a first aqueous phase; (a2) mixing the first organic phase with water and sodium chloride wherein the water has a pH of between 5 and 6; and (a3) mixing the first organic phase and silica gel to prepare the compound of Formula I in a yield of at least 60% and a purity of at least 98%, wherein the compound of Formula I contains less than 1% (w/w) of the compound of Formula X-5: 12. The method of claim 10, wherein the compound of Formula IIa is prepared by: (c) forming a third reaction mixture comprising a Grignard reagent, a compound of Formula III: and 2-bromo-4-(trifluoromethyl)pyridine: wherein the pyridine is present in a molar ratio of 1.0 to 1.5 to the compound of Formula III, and wherein the Grignard reagent is present in a molar ratio of 1.5 to 1.7 to the compound of Formula III, to prepare the compound of Formula IIa. 13. The method of claim 12, wherein the Grignard reagent comprises iPrMgCl or iPrMgBr. 14. The method of claim 12, wherein the Grignard reagent comprises iPrMgBr. 15. The method of claim 12, wherein the third reaction mixture further comprises a third solvent comprising tetrahydrofuran, 2-methyltetrahydrofuran, toluene or xylene. 16. The method of claim 15, wherein the third solvent comprises 2-methyltetrahydrofuran and toluene. 17. The method of claim 12, further comprising the steps of: (c1) adding an acid and water to the third reaction mixture to form a workup mixture; and (c2) distilling the workup mixture to form an intermediate mixture comprising the compound of Formula IIa, 2-methyltetrahydrofuran in an amount of less than 100 ppm, and water in an amount of less than 0.5% (w/w). 18. The method of claim 17, wherein the acid comprises formic acid, acetic acid, propanoic acid, butyric acid, hexanoic acid, octanoic acid, trifluoroacetic acid, or mixtures thereof. 19. The method of claim 17, wherein the acid comprises acetic acid. 20. The method of claim 19, wherein the method of preparing the compound of Formula I comprises: (c) forming the third reaction mixture comprising iPrMgBr, 2-methyltetrahydrofuran, toluene, the compound of Formula III: and 2-bromo-4-(trifluoromethyl)pyridine: wherein the pyridine is present in the molar ratio of about 1.4 to the compound of Formula III, and wherein the Grignard reagent is present in the molar ratio of about 1.65 to the compound of Formula III, to prepare the compound of Formula IIa: (c1) adding acetic acid and water to the third reaction mixture to form the workup mixture; (c2) distilling the workup mixture to form an intermediate mixture comprising the compound of Formula IIa, 2-methyltetrahydrofuran in an amount of less than 100 ppm, and water in an amount of less than 0.5% (w/w); (b) forming the second reaction mixture comprising the intermediate mixture and gaseous HBr, to form the compound of Formula IIb-1 having the structure: and (a) forming the first reaction mixture comprising the compound of Formula IIb-1, triethylamine, and 1-methyl-1H-pyrazole-4-sulfonyl chloride: wherein the sulfonyl chloride is present in the molar ratio of about 1.2 to the compound of Formula IIb-1, to prepare the compound of Formula I in the yield of at least 60% and the purity of at least 98%, wherein the compound of Formula I contains less than 1% (w/w) of the compound of Formula X-5: 21. The method of claim 20, wherein the method further comprises following step (a): (a1) mixing the first reaction mixture with water having the pH of between 4 and 5 to form the first organic phase and the first aqueous phase; (a2) mixing the first organic phase with water and sodium chloride wherein the water has the pH of between 5 and 6; and (a3) mixing the first organic phase and silica gel. 22. A method of purifying a compound of Formula I: or a pharmaceutically acceptable salt thereof, comprising: (a) eluting the compound of Formula I through a High Pressure Liquid Chromatography C18 column using (i) a first mobile mixture comprising water in an amount of at least 95% (v/v), formic acid in an amount of 0.05 to 0.2% (v/v), and acetonitrile in an amount of 1 to 5% (v/v), (ii) a second mobile mixture comprising water in an amount of 45 to 55% (v/v), formic acid in an amount of 0.01 to 0.1% (v/v), and acetonitrile in an amount of 45 to 55% (v/v), and (iii) a third mobile phase comprising water in an amount of 5 to 15% (v/v), formic acid in an amount of 0.005 to 0.02% (v/v), and acetonitrile in an amount of at least 85% (v/v), to form an eluted mixture comprising the compound of Formula I having a purity of at least 98% and the compound of Formula X-5 in an amount of less than 0.75% (w/w): (a1) extracting the compound of Formula I from the eluted mixture into ethyl acetate to form an extracted mixture; (a2) mixing the extracted mixture with methyl t-butyl ether (MTBE) under vacuum to form an MTBE mixture comprising less than 5% (v/v) ethyl acetate; (d) filtering the MTBE mixture through a filter to form a filtered MTBE mixture comprising: the compound of Formula I, the compound of Formula X-5 in an amount of less than 0.5% (w/w), a compound of Formula X-4 in an amount of less than 0.3% (w/w): and a compound of Formula X-6 in an amount of less than 0.25% (w/w): (e) adding the filtered MTBE mixture to heptane to form a precipitated compound of Formula I, wherein the precipitated compound of Formula I comprises 1,4-dibromopentane in an amount of less than 20 ppm; (f) dissolving the precipitated compound of Formula I in methanol to form a methanol mixture; and (g) adding the methanol mixture to water to precipitate the purified compound of Formula I, wherein the purified compound of Formula I has a purity of at least 99%, and comprises the compound of Formula X-5 in an amount of less than 0.5% (w/w), 1,4-dibromopentane in an amount of less than 6 ppm, methyl-1-methyl-1H-pyrazole-4-sulfonate in an amount of less than 6 ppm: and 1-methyl-1H-pyrazole-4-sulfonyl chloride in an amount of less than 6 ppm: 23. The method of claim 22, wherein the purified compound of Formula I has a purity of at least 99%, and further comprises methyl bromide in an amount of less than 20 ppm, and 2-bromopropane in an amount of less than 20 ppm. 24. The method of claim 22, wherein the purified compound of Formula I has a purity of at least 99%, and comprises methyl bromide in an amount of less than 8 ppm, 2-bromopropane in an amount of less than 8 ppm, and 1,4-dibromopentane in an amount of less than 6 ppm. 25. The method of claim 22, wherein the purified compound of Formula I has a purity of at least 99%, and comprises the compound of Formula X-4 in an amount of less than 0.1% (w/w), the compound of Formula X-5 in an amount of less than 0.2% (w/w), the compound of Formula X-6 in an amount of less than 0.2% (w/w), 1,4-dibromopentane in an amount of less than 4 ppm, 1-methyl-1H-pyrazole-4-sulfonyl chloride in an amount of less than 4 ppm, and methyl 1-methyl-1H-pyrazole-4-sulfonate in an amount of less than 4 ppm. 26. The method of claim 22, wherein the purified compound of Formula I has a purity of at least 99%, and further comprises ethyl 1-methyl-1H-pyrazole-4-sulfonate in an amount of less than 6 ppm: and isopropyl 1-methyl-1H-pyrazole-4-sulfonate in an amount of less than 6 ppm: 27. The method of claim 22, wherein the purified compound of Formula I has a purity of at least 99%, and comprises the compound of Formula X-4 in an amount of less than 0.1% (w/w), the compound of Formula X-5 in an amount of less than 0.2% (w/w), the compound of Formula X-6 in an amount of less than 0.2% (w/w), methyl bromide in an amount of less than 4 ppm, 2-bromopropane in an amount of less than 4 ppm, 1,4-dibromopentane in an amount of less than 4 ppm, 1-methyl-1H-pyrazole-4-sulfonyl chloride in an amount of less than 4 ppm, methyl 1-methyl-1H-pyrazole-4-sulfonate in an amount of less than 4 ppm, ethyl 1-methyl-1H-pyrazole-4-sulfonate in an amount of less than 4 ppm, and isopropyl 1-methyl-1H-pyrazole-4-sulfonate in an amount of less than 4 ppm. 28. The method of claim 22, wherein the compound of Formula I is prepared by the method of claim 5. 29. The method of claim 1, wherein HX is wherein R1 is C1-6 alkyl; and subscript n is 1 to 4. 30. The method of claim 29, for preparing the compound of Formula J: or a pharmaceutically acceptable salt thereof, comprises: (a) forming a fourth reaction mixture comprising a compound of Formula IIb-2: and the sulfonyl chloride: to prepare the compound of Formula J in a yield of at least 75% and a purity of at least 98%, wherein X1 is —CH═ or —N═; R1 is C1-6 alkyl; and subscript n is 1 to 4. 31. A method of preparing a compound of Formula I: or a pharmaceutically acceptable salt thereof, comprising: (c) forming a sixth reaction mixture comprising tetrahydrofuran, toluene, iPrMgCl, a compound of Formula III: and 2-bromo-4-(trifluoromethyl)pyridine: wherein the pyridine is present in a molar ratio of about 3.0 to the compound of Formula III, and wherein the Grignard reagent is present in a molar ratio of about 3.05 to the compound of Formula III; (c1) adding acetic acid and water to the sixth reaction mixture to form a workup mixture; (c2) distilling the workup mixture to form an intermediate mixture comprising a compound of Formula IIa: (b) forming a fifth reaction mixture comprising the intermediate mixture, acetonitrile, and methanesulfonic acid, to form a compound of Formula IIb-2: (a) forming a fourth reaction mixture comprising the compound of Formula IIb-2, triethylamine, ethyl acetate, and 1-methyl-1H-pyrazole-4-sulfonyl chloride: wherein the sulfonyl chloride is present in a ratio of about 1.0 to the compound of Formula IIb-2; (a1) adding methanol to the fourth reaction mixture; and (a2) adding water to the reaction mixture to precipitate the compound of Formula I in a yield of at least 75% and a purity of at least 98%. 32. A method of preparing a compound of Formula Ia: or a pharmaceutically acceptable salt thereof, comprising: (c) forming a sixth reaction mixture comprising tetrahydrofuran, toluene, iPrMgCl, a compound of Formula III: and 2-bromo-4-(trifluoromethyl)pyridine: wherein the pyridine is present in a molar ratio of about 3.0 to the compound of Formula III, and wherein the Grignard reagent is present in a molar ratio of about 3.05 to the compound of Formula III; (c1) adding acetic acid and water to the sixth reaction mixture to form a workup mixture; (c2) distilling the workup mixture to form an intermediate mixture comprising a compound of Formula IIa: (b) forming a fifth reaction mixture comprising the intermediate mixture, acetonitrile, and methanesulfonic acid, to form a compound of Formula IIb-2: (a) forming a fourth reaction mixture comprising the compound of Formula Ilb-2, triethylamine, ethyl acetate, and 2-methyl-2H-1,2,3-triazole-4-sulfonyl chloride: wherein the sulfonyl chloride is present in a ratio of about 1.0 to the compound of Formula IIb-2; (a1) adding methanol to the fourth reaction mixture; and (a2) adding water to the reaction mixture to precipitate the compound of Formula Ia in a yield of at least 75% and a purity of at least 98%. 33. A composition comprising: a compound of Formula I in an amount of at least 99% (w/w): and one or more impurity in an amount of from 0.01 to 1% (w/w). 34. The composition of claim 33, wherein the impurity further comprises: a compound of Formula X-D in an amount of less than 0.40% (w/w) and a compound of Formula X-E in an amount of less than 0.40% (w/w) 35. A composition comprising: a compound of Formula Ia in an amount of at least 99% (w/w): and one or more impurity in an amount of from 0.01 to 1% (w/w). 36. A crystalline form of (R)-(1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoro methyl)pyridin-2-yl)methanone tris-methanesulfonic acid: characterized by an X-ray powder diffraction (XRPD pattern having peaks at about 5.0°, 9.9°, 14.5°, 16.5°, 17.6°, 17.9°, 18.2°, 18.3°, 19.0°, 19.7°, 20.8°, 22.9°, 23.4°, and 25.3°, 2-θ±0.2° 2-θ. 37. A pharmaceutical composition comprising a composition of claim 33, and one or more pharmaceutically acceptable excipients. 38. A method of treating a disorder or condition through modulating a glucocorticoid receptor, comprising administering to a subject in need of such treatment, a therapeutically effective amount of a composition of claim 33, thereby treating the disorder or condition. 39. A method of treating a disorder or condition through antagonizing a glucocorticoid receptor, comprising administering to a subject in need of such treatment, a therapeutically effective amount of a composition of claim 33, thereby treating the disorder or condition. 40. A method of treating fatty liver disease, comprising administering to a subject in need thereof, a therapeutically effective amount of a composition of claim 33, thereby treating fatty liver disease. 41. A method of treating antipsychotic induced weight gain, comprising administering to a subject in need thereof, a therapeutically effective amount of the crystalline form of claim 33, thereby treating antipsychotic induced weight gain.